A Randomised, Open-label, Cross-over Study of Flutiform® BAI and Flutiform® pMDI Devices in Adolescents and Adult Subjects With Persistent Asthma or Chronic Obstructive Pulmonary Disease (COPD) to Assess Patient Handling.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 332
- 试验地点
- 2
- 主要终点
- Measurement of successful device use (Flutiform® pMDI) versus (breath activated device (BAI))
研究概览
简要总结
This study will compare the patient handling of Flutiform® pMDI (pressurised metered dose inhaler) and a breath activated device (BAI). Patient handling will be assessed using assessment criteria which detail the correct handling steps for each inhaler.
详细描述
Approximately 340 subjects aged 12 years and over who have asthma or chronic obstructive pulmonary disease (COPD), and are on medication for their condition will be recruited for the study. Subjects will be recruited to ensure that different severities of disease are included in the study.
Severity of disease will be determined by predicted FEV1. During the study subjects will be trained to use both the pMDI device and the BAI device being compared. Following training the subjects' use of each device will be assessed by a trainer/assessor using assessment criteria which cover handling, actuation and inhalation aspects for each of the devices under test. The order in which subjects receive each device will be determined using a randomisation schedule.
During the study subjects will continue to take their prescribed asthma or COPD medication. The pMDI and BAI devices used for the patient handling assessment will only contain placebo.
The duration of the study for a subject will be up to 58 days. Training and use of each device will be separated by 7 to 21 days
研究设计
- 研究类型
- Observational
- 观察模型
- Case Crossover
- 时间视角
- Prospective
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent/assent.
- •Male and female subjects ≥12 years old.
- •Documented history of asthma or COPD for ≥ 6 months prior to screening visit.
- •Subjects receiving ICS and LABA
- •Can perform spirometry adequately.
- •Willing and able to attend all study visits
排除标准
- •Any severe chronic respiratory disease other than asthma and COPD.
- •Evidence of a clinically unstable disease as determined by medical history or physical examination that, in the Investigator's opinion, precludes entry into the study or may confound between-period comparisons. 'Clinically unstable' is defined as any disease that, in the opinion of the Investigator, would put the Subject at risk through study participation.
- •Any serious neuromuscular disorder, or orofacial disease preventing the application of an inhaler to the mouth.
- •Known sensitivity to inhaler propellant or excipients.
- •Participation in a clinical drug study within 30 days of the screening visit.
- •Current participation in a clinical study.
结局指标
主要结局
Measurement of successful device use (Flutiform® pMDI) versus (breath activated device (BAI))
时间窗: One day only for each device
This study compares our Flutiform® pMDI (pressurised metered dose inhaler) containing placebo only and a breath activated device (BAI), containing placebo only. The percentage of subjects will be measured who have successful device use using an 8 point scale.
次要结局
- The percentage of subjects able to generate an adequate inspiratory flow to trigger the BAI.(Each device will be used on one day only)
- The percentage of subjects with successful device use(Each device will be used for one day only)
- The percentage of subjects unable to be trained to use the device successfully within 15 minutes(Each device will be used on one day only)
- The percentage of subjects able to perform 7, 6, 5, 4, 3, 2, and 1 step successfully.(Each device will be used for one day only)